Luxembourg's Acceleration Programme Fit 4 Start Call for ICT and Space Tech Applications Open
12.12.2019 17:26:00 EET | Business Wire | Press release
Fit 4 Start is Luxembourg’s acceleration programme for supporting start-ups. Start-ups benefitting from the programme, established in Luxembourg or another country, including outside the European Union, are selected twice a year. Launched by the Ministry of the Economy and managed by Luxinnovation, the Fit 4 Start programme has opened its next call for candidates for national and international start-ups.
The next edition of Fit 4 Start is aimed at young innovative companies active in the information and communication technologies sector (ICT) as well as the space technology sector. Registrations can be made online up until 20 January 2020 at 12.00 hours (midday Luxembourg time) via www.fit4start.com.
A pre-selection is carried out on the basis of the applications received. Candidates who are pre-selected will be notified on 3 February 2020. The pre-selected start-ups then meet for a ‘pitching’ session organised during the ‘Pitching and Graduation day’ which will take place on 26 March 2020 in Luxembourg City. 10 ICT and 5 space technology start-ups will be selected by an international jury to take part in the 10th edition.
Fit 4 Start offers to the 15 successful candidates a grant of €50,000, personalised and intensive coaching as well as free co-working space during four months at one of two incubator partners, Technoport and the Luxembourg City Incubator. An additional grant of €100,000 is awarded to start-ups which have successfully completed the programme and which have managed to raise at least €50,000 in private capital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005454/en/
Contact information
Ministry of the Economy
Paul Zenners
Email: paul.zenners@eco.etat.lu
Tel.: (+352) 247-74126
Mobile: (+352) 621 409 141
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release
Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom